Cluster Headache Treatment Market Size, Share, Growth, Research and Forecast 2019-2025


Posted May 13, 2020 by globalomr

Cluster Headache Treatment Market Size, Share, & Trend Analysis Report, By Treatment (Drug (Triptans, Octreotide, Dihydroergotamine, and Others) and Device), and Forecast Period 2019-2025

 
The growing development in the drugs and technological advancement in the treatment of cluster headache is the major factor encouraging the growth of the global cluster headache treatment market. For instance, in June 2019, Eli Lilly and Co. granted the US Food and Drug Administration (FDA) approval for Emgality (Galcanezumab). The drug that helps in decreasing the frequency of attacks in episodic cluster headache patients. It is the first FDA approved drug for the treatment of Episodic Cluster Headache. It helps in reducing the chances of migraines in cluster headache affected patients. The safety of Emgality was evaluated in three clinical trials that include more than 2,500 patients. The hypersensitivity reaction has been reported with Emgality in clinical studies. The most common reaction with the use of Emgality is injection site reactions.

A full report of Global Cluster Headache Treatment Market is available at: https://www.omrglobal.com/industry-reports/cluster-headache-treatment-market

In April 2017, ElectroCore Medical plc received approval for GammaCore devices from the US FDA. GammCore is a non-invasive vagus nerve stimulator designed with the aim to cure pain in the episodic cluster headache in adults. It is the first FDA approved device used for the treatment of episodic cluster headache. GammaCore is a safe, efficient, and effective way for the treatment of cluster headache with respect to other available treatments. The FDA approved gammCore has the new technological advancement in the treatment of pain associated with the cluster headache. It does not have any side effects of using this device and also there is no dose limit for it as it was prescribed for other cluster headache treatments.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/cluster-headache-treatment-market

• In September 2018, ElectrCore started serving its episodic cluster treatment with GammaCore sapphire therapy in the US to expand its geographical presence as the US has the huge market for cluster headache treatment with around more than 0.35 million people suffering from cluster headache provides a huge opportunity for the company as well as the market to grow.
• In March 2017, Autonomic Technologies announced the received of expanded indication (CE) mark in Europe for the Pulsante SPG Microstimulator Systems. Pulsante SPG Microstimulator Systemis the first implantable neurostimulation therapy to receive CE mark for pain relief in both cluster headache and certain types of migraine. The Pulsante SPG Microstimulator System is activated using an external remote controller that enables the patient to deliver as-needed stimulation to relieve the attack.

Cluster Headache Treatment Market Segmentation

By Treatment

• Drug
o Triptans
o Octreotide
o Dihydroergotamine
o Others
• Devices

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/cluster-headache-treatment-market

Cluster Headache Treatment Market– Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• AstraZeneca PLC
• Aurobindo Pharma, Ltd.
• Autonomic Technologies, Inc.
• Dr. Reddy's Laboratories, Ltd.
• ElectroCore Medical LLC
• Eli Lilly and Company
• Fresenius Kabi Pharmaceuticals Holding, Inc.
• GlaxoSmithKline PLC
• Janssen Pharmaceuticals, Inc.
• LGM Pharma, LLC
• Merck KGaA
• Mylan N.V.
• Novartis AG
• Par Pharmaceutical Companies, Inc.
• Ranbaxy Laboratories, Ltd.
• Sagent Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• TrioxBio Inc.
• Winston Pharmaceuticals Inc.

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 7803040404
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Arti Sharma
Phone +91 7803040404
Business Address 305-308, Commerce House, Janjeerwala Square, Indore, Madhya Pradesh 452001
Country India
Categories Health , Medical , Research
Tags headache , healthcare , pharmaceuticals
Last Updated May 13, 2020